| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2008.10.013 |
| P698 | PubMed publication ID | 18951941 |
| P50 | author | Yassine Chtourou | Q42747577 |
| Koussay Dellagi | Q95146463 | ||
| P2093 | author name string | Sami Ben Hadj Ahmed | |
| Chokri Bahloul | |||
| Leila Touihri | |||
| P2860 | cites work | DNA vaccines: immunology, application, and optimization* | Q28145651 |
| Leishmania/HIV co-infections: epidemiology in Europe. | Q30336421 | ||
| Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis | Q33796005 | ||
| Leishmaniasis: current status of vaccine development | Q33941719 | ||
| Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease | Q34008104 | ||
| Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis | Q34008441 | ||
| Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response | Q34008582 | ||
| Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice | Q34123352 | ||
| Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis | Q34128082 | ||
| Type 1 and type 2 responses to Leishmania major | Q34635606 | ||
| Evasion of innate immunity by parasitic protozoa | Q34983845 | ||
| Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice | Q35118989 | ||
| HIV and the transmission of Leishmania | Q35609024 | ||
| DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis | Q36376098 | ||
| The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice | Q36376320 | ||
| Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major | Q36380692 | ||
| The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge | Q37227569 | ||
| Evaluation of the murine immune response to Leishmania meta 1 antigen delivered as recombinant protein or DNA vaccine. | Q40694366 | ||
| Multiple pathways for the initiation of T helper 2 (Th2) responses | Q42947603 | ||
| Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge | Q43223330 | ||
| A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major | Q43604612 | ||
| A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. | Q43861566 | ||
| Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant | Q44126498 | ||
| Genetic vaccination against leishmaniasis | Q45026373 | ||
| Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis | Q45889225 | ||
| Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice | Q46946752 | ||
| A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major | Q47805253 | ||
| Optimization of DNA vaccination against cutaneous leishmaniasis. | Q52009810 | ||
| The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. | Q52020458 | ||
| Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. | Q53609100 | ||
| Therapy of murine cutaneous leishmaniasis by DNA vaccination. | Q54050407 | ||
| Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani | Q56749822 | ||
| Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-γ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge | Q58824983 | ||
| Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis | Q63408514 | ||
| Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells | Q73948770 | ||
| Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection | Q77489424 | ||
| Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection | Q77658710 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 99-106 | |
| P577 | publication date | 2008-10-23 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice | |
| P478 | volume | 27 |
| Q35517074 | An overview on Leishmania vaccines: A narrative review article |
| Q33633286 | BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge |
| Q39278829 | Cloning of a Recombinant Plasmid Encoding Thiol-Specific Antioxidant Antigen (TSA) Gene of Leishmania majorand Expression in the Chinese Hamster Ovary Cell Line. |
| Q30578697 | Combined immunization using DNA-Sm14 and DNA-Hsp65 increases CD8+ memory T cells, reduces chronic pathology and decreases egg viability during Schistosoma mansoni infection |
| Q40105761 | Comparative Assessment of Induced Immune Responses Following Intramuscular Immunization with Fusion and Cocktail of LeIF, LACK and TSA Genes Against Cutaneous Leishmaniasis in BALB/c Mice |
| Q38081358 | DNA immunization as an efficient strategy for vaccination |
| Q37682900 | DNA vaccines: a rational design against parasitic diseases. |
| Q35688323 | Efficacy of Recombinant Canine Distemper Virus Expressing Leishmania Antigen against Leishmania Challenge in Dogs |
| Q33732102 | Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins |
| Q41404819 | Head-to-head comparison of three vaccination strategies based on DNA and raw insect-derived recombinant proteins against Leishmania. |
| Q37053209 | Immune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania major |
| Q90055472 | Immunization against Leishmania major infection in BALB/c mice using a subunit-based DNA vaccine derived from TSA, LmSTI1, KMP11, and LACK predominant antigens |
| Q37773297 | Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature. |
| Q52659333 | Induction of Immune Responses by DNA Vaccines Formulated with Dendrimer and Poly (Methyl Methacrylate) (PMMA) Nano-Adjuvants in BALB/c Mice Infected with Leishmania major. |
| Q39284066 | The immune response induced by DNA vaccine expressing nfa1 gene against Naegleria fowleri. |
| Q34724869 | Vaccination with lentiviral vector expressing the nfa1 gene confers a protective immune response to mice infected with Naegleria fowleri |
Search more.